Placebos are medications or interventions that do not have a true treatment effect on the symptom or disease for which they are used 1 . They are usually inert substances such as sugar pills or saline, or sham procedures. However, placebos may still influence the symptom or disease through a 'placebo effect' 1 . This effect can provide real benefits for patients, although its magnitude and duration may vary. The mechanism of the placebo effect has been well studied and is related to classical conditioning, patient expectancy and patients' desire for a favourable outcome 1, 2 . There is often a neurobiological or immunological basis 1, 2 . In other words, the placebo effect is real.
In clinical research, a placebo is used for two main purposes 3 . The first is to ensure blinding of both patients and researchers. The second is to differentiate the true treatment effect from the placebo effect. If a test drug is superior to a placebo, a direct therapeutic effect over and above a placebo effect can be inferred. If there is no difference, then the test drug is no better than a placebo. This is not the same as the test drug is no better than no treatment.
A placebo control is not required for all clinical trials 3 . Comparison of the test drug to a placebo provides information of the absolute efficacy of a test drug, but not its efficacy relative to a standard alternative 4, 5 . Clinicians will still not know whether the test drug is superior to standard therapy. Moreover, the use of a placebo may deny patients the benefits of a standard alternative. Therefore, if a standard alternative is available, a standard therapy control may be more appropriate.
In this issue of the journal there are three placebo-controlled trials. Rapchuk et al assessed the effect of gabapentin on pain after cardiac surgery 4 . Gabapentin or placebo was given in addition to standard treatment. This was an appropriate use of a placebo control because neither group was denied standard therapy. Similar considerations apply to the trial by Ghai et al 5 . However, the trial by Huh et al is more complicated 6 . They assessed the anti-emetic efficacy of midazolam when added to morphine patient-controlled analgesia solutions, by comparing it to the addition of ondansetron, a known effective anti-emetic agent. They found that midazolam had similar anti-emetic efficacy to ondansetron when used in this way. However, they had a third group, which was morphine patient-controlled analgesia with no prophylactic anti-emetic (i.e. placebo). Not unexpectedly, the placebo group had a much higher incidence of postoperative nausea and vomiting. From this study, readers can be relatively sure that either midazolam or ondansetron added to morphine patient-controlled analgesia solutions will have superior anti-emetic efficacy to placebo. However, they will not know whether either drug used in this way will be superior to a more standard form of prophylaxis (e.g. a single dose anti-emetic drug).
The placebo effect has implications for clinical practice as well as clinical research. This is because the 'placebo effect' is not limited to placebos! Active drugs may also have a placebo effect, over and above their direct therapeutic effect 2, 7 . In fact, it may be that the doctor/patient interaction is the most important factor in a placebo effect, and not the drug or intervention 2, 7 . However, the essential feature of a placebo effect is that patients must believe that they are, or that they might be, receiving an active treatment. This means that drugs used in unconscious patients cannot have a placebo effect, unless patients are advised of the treatment given. As the 'placebo effect' is often real, failure to advise patients of the treatment may result in less than maximal benefit. Therefore, physicians should take every opportunity to inform patients of the drugs they are given and describe them in the most favourable light, although avoiding unrealistic expectations. Physicians should also appreciate the powerful influence of positive patient interactions on the quality of outcomes. This may be described as a 'placebo effect'. It may also be described as the 'art of medicine' 7 .
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